Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Autor:	Acs M; Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany.; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Babucke M; Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany., Jusufi M; Department of General and Visceral Surgery, AK Barmbek, Hamburg, Germany., Kaposztas Z; Department of Surgery, Somogy County Kaposi Mor Teaching Hospital, Kaposvar, Hungary., Slowik P; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Hornung M; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Schlitt HJ; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Panczel I; Faculty of Medicine, Semmelweis University, Budapest, Hungary., Hevesi J; University of Regensburg, Regensburg, Germany., Herzberg J; Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany., Strate T; Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany., Piso P; Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany.
Jazyk:	angličtina
Zdroj:	Innovative surgical sciences [Innov Surg Sci] 2024 Mar 14; Vol. 9 (1), pp. 3-15. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).
DOI:	10.1515/iss-2023-0055
Abstrakt:	Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled problems, as there are many uncertain aspects considering the outcomes of affected patients' prognoses. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are associated with favorable long-term outcomes in carefully selected patients with peritoneal metastases (PM). We aim to summarize the current results about the initial malignancies and their peritoneal spreads. The current literature has been scrutinized, and studies between 2016 and 2022 were included wherein long-term, progression-free (PFS), and overall survival (OS) data were considered relevant information. Medline, Embase, and Google Scholar have been the main sources. Hereby, we cover all the primer malignancies: gastric, ovarian, and colorectal cancers with peritoneal metastases (PM), malignant peritoneal mesothelioma, and pseudomyxoma peritonei. Examining the advances in the current peer-reviewed literature about the indications of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), target groups, risk factors, and other influencing elements, we intend to provide a complex state-of-the-art report, establishing the relevant aspects of that emerging treatment method. Competing Interests: Competing interests: The authors state no conflict of interest. (© 2024 the author(s), published by De Gruyter, Berlin/Boston.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu